Total Payments
$3,472
2024 Payments
$834.88
Companies
27
Transactions
189
Medicare Patients
3,917
Medicare Billing
$432,122
Payment Breakdown by Category
Food & Beverage$3,270 (94.2%)
Education$202.33 (5.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,270 | 185 | 94.2% |
| Education | $202.33 | 4 | 5.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,169 | 72 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $305.30 | 18 | $0 (2024) |
| PFIZER INC. | $248.02 | 13 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $199.49 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $190.91 | 5 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $150.15 | 11 | $0 (2021) |
| Boston Scientific Corporation | $144.74 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $110.37 | 5 | $0 (2019) |
| Covidien LP | $106.30 | 2 | $0 (2019) |
| Celltrion USA Inc. | $102.08 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $834.88 | 48 | ABBVIE INC. ($164.20) |
| 2023 | $567.56 | 34 | AbbVie Inc. ($223.53) |
| 2022 | $438.24 | 25 | ABBVIE INC. ($237.59) |
| 2021 | $434.16 | 28 | AbbVie Inc. ($151.29) |
| 2020 | $84.33 | 6 | AbbVie Inc. ($30.76) |
| 2019 | $546.13 | 23 | AbbVie, Inc. ($152.24) |
| 2018 | $366.49 | 20 | AbbVie, Inc. ($209.45) |
| 2017 | $200.55 | 5 | Janssen Biotech, Inc. ($99.95) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 3 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: VIROLOGY | ||||||
| 12/11/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/07/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/29/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/17/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $10.78 | General |
| Category: VIROLOGY | ||||||
| 11/15/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/15/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/02/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $14.39 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/01/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.25 | General |
| 10/24/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.49 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.31 | General |
| Category: Neuroscience | ||||||
| 10/11/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.82 | General |
| Category: Neuroscience | ||||||
| 09/26/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $96.37 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/25/2023 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Antibiotic | ||||||
| 09/18/2023 | AbbVie Inc. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $2.60 | General |
| Category: VIROLOGY | ||||||
| 08/21/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/21/2023 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $29.54 | General |
| Category: Antibiotic | ||||||
| 07/19/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/11/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $15.72 | General |
| Category: THERAPY FOR CSID | ||||||
| 06/29/2023 | AbbVie Inc. | LINZESS (Drug), VIBERZI | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/16/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,597 | 2,057 | $808,454 | $187,412 |
| 2022 | 20 | 1,119 | 1,420 | $505,751 | $117,926 |
| 2021 | 22 | 867 | 946 | $494,894 | $89,467 |
| 2020 | 11 | 334 | 371 | $291,863 | $37,317 |
Total Patients
3,917
Total Services
4,794
Medicare Billing
$432,122
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 309 | $78,177 | $27,940 | 35.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 239 | 239 | $78,153 | $27,190 | 34.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 216 | 306 | $61,200 | $26,767 | 43.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 161 | 412 | $57,680 | $24,525 | 42.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 100 | 100 | $88,300 | $12,669 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 139 | $24,881 | $8,957 | 36.0% |
| 43264 | Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | Facility | 2023 | 40 | 40 | $28,360 | $8,562 | 30.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 47 | 48 | $32,736 | $7,917 | 24.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 110 | 110 | $84,370 | $7,319 | 8.7% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 48 | 51 | $117,147 | $4,630 | 4.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 50 | 54 | $32,184 | $4,444 | 13.8% |
| 43274 | Insertion of stent into pancreatic or bile duct using a flexible endoscope | Facility | 2023 | 12 | 14 | $12,614 | $4,384 | 34.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 14 | 14 | $12,362 | $3,609 | 29.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 77 | 77 | $10,934 | $3,030 | 27.7% |
| 43237 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | Facility | 2023 | 22 | 22 | $8,382 | $2,911 | 34.7% |
| 43238 | Ultrasound guided needle aspiration or biopsy of esophagus using a flexible endoscope | Facility | 2023 | 15 | 16 | $7,232 | $2,622 | 36.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $13,640 | $2,606 | 19.1% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 16 | $21,424 | $2,413 | 11.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 14 | 14 | $12,810 | $2,209 | 17.2% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 11 | 11 | $4,268 | $1,657 | 38.8% |
| 43262 | Incision of pancreatic outlet using a flexible endoscope | Facility | 2023 | 30 | 30 | $20,850 | $786.30 | 3.8% |
| 74328 | Review by radiologist of image from tube placement into bile duct using an endoscope | Facility | 2023 | 15 | 15 | $750.00 | $265.35 | 35.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 199 | 276 | $55,200 | $21,497 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 148 | 148 | $48,396 | $17,141 | 35.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 119 | 287 | $40,180 | $15,336 | 38.2% |
About Avery Smith
Avery Smith is a Gastroenterology healthcare provider based in Abilene, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2014. The National Provider Identifier (NPI) number assigned to this provider is 1578983771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Avery Smith has received a total of $3,472 in payments from pharmaceutical and medical device companies, with $834.88 received in 2024. These payments were reported across 189 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($3,270).
As a Medicare-enrolled provider, Smith has provided services to 3,917 Medicare beneficiaries, totaling 4,794 services with total Medicare billing of $432,122. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Abilene, TX
- Active Since 04/27/2014
- Last Updated 01/11/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578983771
Products in Payments
- Humira (Biological) $272.39
- RINVOQ (Biological) $235.86
- XELJANZ (Drug) $212.18
- DUPIXENT (Biological) $199.49
- MAVYRET (Drug) $161.98
- LINZESS (Drug) $139.31
- DIFICID (Drug) $136.97
- ENTYVIO (Biological) $120.60
- CREON (Drug) $112.88
- Kanuma (Drug) $110.37
- HYDRATOME (Device) $108.68
- REMICADE (Biological) $99.95
- TREMFYA (Drug) $90.96
- Entyvio (Biological) $87.81
- ELEVIEW (Device) $81.78
- OCALIVA (Drug) $78.47
- VEGZELMA (Biological) $78.46
- HUMIRA (Biological) $73.36
- VOWST (Biological) $71.58
- XIFAXAN (Drug) $65.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.